16/05/2018 16:30:12

Bavarian Nordic to Host First Quarter 2018 Results Conference Call

Related content
16 May - 
Bavarian Nordic Announces Acceptance of Abstracts and O..
02 May - 
Bavarian Nordic Receives FDA Orphan Drug Designation fo..
30 Apr - 
Bavarian Nordic A/S - Articles of Association
Related debate
20 May - 
"The WHO is sending 7,540 doses of the vaccine develope..
20 May - 
https://finance.yahoo.com/news/congo-begin-ebola-vaccin..
20 May - 
God fornøjelse - husk at fortælle, hvad du får ud af di..

COPENHAGEN, Denmark -

May 16

, 201

8 - Bavarian Nordic A/S (OMX:  BAVA, OTC: BVNRY) will announce its 2018 first quarter results on Thursday, May 24, 2018.

The management of Bavarian Nordic will host a conference call at 2:00 pm CEST (8:00 am EDT) on the same day to present the interim results followed by a Q&A session. A live and replay version of the call and relevant slides will be available at http://bit.ly/2KzQlN2.

To join the Q&A session dial one of the following numbers and state the participant code 8332812: Denmark: +45 35 15 81 21, UK: +44 (0) 330 336 9411, USA: +1 323-794-2551.

Contacts

Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Phone +45 61 77 47 43

U.S.: Seth Lewis, Vice President, Investor Relations & Communications. Phone: +1 978 341 5271

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development of innovative and safe therapies against cancer and infectious diseases. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates intended to improve the health and quality of life for children and adults. We supply our IMVAMUNE® non-replicating smallpox vaccine to the U.S. Strategic National Stockpile and other government stockpiles. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Registration studies are currently underway in the U.S. In addition to our long-standing collaboration with the U.S. government on the development of IMVAMUNE® and other medical countermeasures, our infectious disease pipeline comprises a proprietary RSV program as well as vaccine candidates for Ebola, HPV, HBV and HIV, which are developed through a strategic partnership with Janssen. Additionally, in collaboration with the National Cancer Institute, we have developed a portfolio of active cancer immunotherapies, designed to alter the disease course by eliciting a robust and broad anti-cancer immune response while maintaining a favorable risk-benefit profile. Through multiple industry collaborations, we seek to explore the potential synergies of combining our immunotherapies with other immune-modulating agents, e.g. checkpoint inhibitors.

For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 May
BAVA
Som lovet ville jeg vende tilbage i kurs 210. Tillykke til alle. Jeg holder. Kurs 250-260 kommer sna..
9
15 May
BAVA
Her er en beroligelse til de investorer, der undrer sig over, at WHO har valgt Mercks ebola-vaccine ..
8
18 May
BAVA
jeg tror den stiger når USA åbner, der er flere gode nyheder
6
14 May
BAVA
Hvis det er scenariet for at Bavarian ryger i 5000, så ser jeg hellere den ryger i 0.
6
18 May
BAVA
Vi hæver i dag anbefalingen på Bavarian Nordic til Køb fra Hold med kursmål DKK 290. Det svarer til ..
5
17 May
BAVA
https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=481496013&sourcecode=ddk   Hvord..
5
16 May
BAVA
Vær dog seriøs og læs op på casen, og du vil se, at Bava har likviditet nok til, at der igen kommer ..
5
17 May
BAVA
Baron, man skal altså ikke tro på alt det man læser......tænk hvis man skulle tro på alt det du skri..
4
16 May
BAVA
i PREVAC tester de Mercks vaccine hvor de bruger samme vaccine igen efter 8 uger.   Er ikke i tvivl ..
4
17 May
BAVA
Bavarian Nordic har fået accept af at kunne fremføre fem præsentationer på den kommende ASCO-konfere..
3

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Lambert Catches Record-Breaking Limit to Take Lead after Day Three of FLW Tour at Kentucky Lake Presented by Costa Sunglasses
2
ALGT LOSS ALERT: Rosen Law Firm Reminds Allegiant Travel Company Investors of Important Deadline in Class Action– ALGT
3
TheRecover.com, Drug Detoxification For San Jose Residents
4
PRF: Consolidated Unaudited Interim Report of AS PRFoods for 1st quarter of 2018 and 15 months of 2017/2018
5
TheRecover.com, Columbus Drug Rehabs Can Help

Related stock quotes

Bavarian Nordic A/S 204.00 7.6% Stock price increasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 May 2018 02:00:54
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180515.2 - EUROWEB5 - 2018-05-21 03:00:54 - 2018-05-21 02:00:54 - 1000 - Website: OKAY